Neuroimaging characteristics of dementia with Lewy bodies

详细信息    查看全文

• 作者：Elijah Mak ; Li Su ; Guy B Williams ; John T O’Brien
• 刊名：Alzheimer's Research & Therapy
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：6
• 期：2
• 全文大小：280 KB
• 参考文献：1. McKeith, IG, Dickson, DW, Lowe, J, Emre, M, O'Brien, JT, Feldman, H, Cummings, J, Duda, JE, Lippa, C, Perry, EK, Aarsland, D, Arai, H, Ballard, CG, Boeve, B, Burn, DJ, Costa, D, Del Ser, T, Dubois, B, Galasko, D, Gauthier, S, Goetz, CG, Gomez-Tortosa, E, Halliday, G, Hansen, LA, Hardy, J, Iwatsubo, T, Kalaria, RN, Kaufer, D, Kenny, RA, Korczyn, A (1863-872) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005: pp. 65
  2. Piggott, MA, Marshall, EF, Thomas, N, Lloyd, S, Court, JA, Jaros, E, Burn, D, Johnson, M, Perry, RH, McKeith, IG, Ballard, C, Perry, EK (1999) Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 122: pp. 1449-1468 CrossRef
  3. O'Brien, JT, Colloby, S, Fenwick, J, Williams, ED, Firbank, M, Burn, D, Aarsland, D, McKeith, IG (2004) Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61: pp. 919-925 CrossRef
  4. McKeith, I, O'Brien, J, Walker, Z, Tatsch, K, Booij, J, Darcourt, J, Padovani, A, Giubbini, R, Bonuccelli, U, Volterrani, D, Holmes, C, Kemp, P, Tabet, N, Meyer, I, Reininger, C (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6: pp. 305-313 CrossRef
  5. Walker, Z, Jaros, E, Walker, RW, Lee, L, Costa, DC, Livingston, G, Ince, PG, Perry, R, McKeith, I, Katona, CL (2007) Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78: pp. 1176-1181 CrossRef
  6. Roselli, F, Pisciotta, NM, Perneczky, R, Pennelli, M, Aniello, MS, De Caro, MF, Ferrannini, E, Tartaglione, B, Defazio, G, Rubini, G, Livrea, P (2009) Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov Disord 24: pp. 2097-2103 CrossRef
  7. O'Brien, JT, McKeith, IG, Walker, Z, Tatsch, K, Booij, J, Darcourt, J, Marquardt, M, Reininger, C (2009) Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 194: pp. 34-39 CrossRef
  8. Lobotesis, K, Fenwick, JD, Phipps, A, Ryman, A, Swann, A, Ballard, C, McKeith, IG, O'Brien, JT (2001) Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 56: pp. 643-649 CrossRef
  9. Minoshima, S, Foster, NL, Petrie, EC, Albin, RL, Frey, KA, Kuhl, DE (2002) Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology. J Geriatr Psychiatry Neurol 15: pp. 200-209 CrossRef
  10. Hanyu, H, Shimizu, S, Hirao, K, Kanetaka, H, Sakurai, H, Iwamoto, T, Koizumi, K, Abe, K (2006) Differentiation of dementia with Lewy bodies from Alzheimer's disease using Mini-Mental State Examination and brain perfusion SPECT. J Neurol Sci 250: pp. 97-102 CrossRef
  11. Ishii, K, Yamaji, S, Kitagaki, H, Imamura, T, Hirono, N, Mori, E (1999) Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology 53: pp. 413-416 CrossRef
  12. Colloby, SJ, Taylor, JP, Firbank, MJ, McKeith, IG, Williams, ED, O'Brien, JT (2010) Covariance 99mTc-exametazime SPECT patterns in Alzheimer's disease and dementia with Lewy bodies: utility in differential diagnosis. J Geriatr Psychiatry Neurol 23: pp. 54-62 CrossRef
  13. Colloby, SJ, Taylor, JP, Davison, CM, Lloyd, JJ, Firbank, MJ, McKeith, IG, O'Brien, JT (2013) Multivariate spatial covariance analysis of 99mTc-exametazime SPECT images in
• 刊物主题：Neurosciences; Neurology; Geriatrics/Gerontology;
• 出版者：BioMed Central
• ISSN：1758-9193

文摘

This review summarises the findings and applications from neuroimaging studies in dementia with Lewy bodies (DLB), highlighting key differences between DLB and other subtypes of dementia. We also discuss the increasingly important role of imaging biomarkers in differential diagnosis and outline promising areas for future research in DLB. DLB shares common clinical, neuropsychological and pathological features with Parkinson’s disease dementia and other dementia subtypes, such as Alzheimer’s disease. Despite the development of consensus diagnostic criteria, the sensitivity for differential diagnosis of DLB in clinical practice remains low and many DLB patients will be misdiagnosed. The importance of developing accurate imaging markers in dementia is highlighted by the potential for treatments targeting specific molecular abnormalities as well as the responsiveness to cholinesterase inhibitors and marked neuroleptic sensitivity of DLB. We review various brain imaging techniques that have been applied to investigate DLB, including the characteristic nigrostriatal degeneration in DLB using positron emission tomography (PET) and single-photon emission computed tomography (SPECT) tracers. Dopamine transporter loss has proven to reliably differentiate DLB from other dementias and has been incorporated into the revised clinical diagnostic criteria for DLB. To date, this remains the 'gold standard' for diagnostic imaging of DLB. Regional cerebral blood flow, 18?F-fluorodeoxygluclose-PET and SPECT have also identified marked deficits in the occipital regions with relative sparing of the medial temporal lobe when compared to Alzheimer’s disease. In addition, structural, diffusion, and functional magnetic resonance imaging techniques have shown alterations in structure, white matter integrity, and functional activity in DLB. We argue that the multimodal identification of DLB-specific biomarkers has the potential to improve ante-mortem diagnosis and contribute to our understanding of the pathological background of DLB and its progression.